BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris

Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: BMS Chooses Houston for $2.3B Manufacturing FacilityBy Alex Philippidis, GEN Edge, Aug 10, 2026Next 10 U.S. Biopharma ClustersBy Alex Philippidis, GEN, Aug 12, 2026Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI MapBy Alex Philippidis, GEN Edge, Aug 5, 2026COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVIDGEN, Aug 5, 2026Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir ExplainedBy Alex Philippidis, GEN, Oct 5, 2020Lessons from the COVID Crisis: An Interview with Peter HotezBy Alex Philippidis, GEN Edge, Oct 19, 2022How to Conquer Coronavirus: Top 35 Treatments in DevelopmentBy Alex Philippidis, GEN, March 2, 2020Candida auris Persists in Hair Follicles, Hijacks Immune SignalingGEN, August 10, 2026The State of Biotech SummitSeptember 23, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD  Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD  The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026Subscribe to GEN’s newsletters Hosted on Acast. See acast.com/privacy for more information.